References

Cognitive impairment in schizophrenia

10.1007/978-3-642-25758-2_2 · 2012 · External reference

Time for new schizophrenia Rx

10.1126/science.1252603 · 2014 · External reference

The NMDA receptor ‘glycine modulatory site’ in schizophrenia: d-serine, glycine, and beyond

10.1016/j.coph.2014.12.004 · 2015 · External reference

Identifying pathways leading to prefrontal GABA-ergic interneuron dysfunction in schizophrenia

10.1176/appi.ajp.2014.14060750 · 2014 · External reference

Lower expression of glutamic acid decarboxylase 67 in the prefrontal cortex in schizophrenia: contribution of altered regulation by Zif268

10.1176/appi.ajp.2014.14010004 · 2014 · External reference

GABAergic interneurons: implications for understanding schizophrenia and bipolar disorder

10.1016/s0893-133x(01)00225-1 · 2001 · External reference

Differential expression of c-fos and zif268 in rat striatum after haloperidol, clozapine, and amphetamine

10.1073/pnas.89.10.4270 · 1992 · External reference

A possible role for the striatum in the pathogenesis of the cognitive symptoms of schizophrenia

10.1016/j.neuron.2010.02.014 · 2010 · External reference

F15063, a potential antipsychotic with dopamine D(2)/D(3) receptor antagonist and 5-HT(1A) receptor agonist properties: influence on immediate-early gene expression in rat prefrontal cortex and striatum

10.1016/j.ejphar.2009.08.019 · 2009 · External reference

Atypical antipsychotic drugs, quetiapine, iloperidone, and melperone, preferentially increase dopamine and acetylcholine release in rat medial prefrontal cortex: role of 5-HT1A receptor agonism

10.1016/s0006-8993(02)03570-9 · 2002 · External reference

Clozapine to n-desmethylclozapine plasma concentrations ratio predicts working memory performance in schizophrenia

10.1176/appi.ajp.2015.14050673 · 2015 · External reference

Attention must be paid: the plasma clozapine/N-desmethylclozapine (NDMC) ratio association with working memory and its relevance to the treatment of Cognitive Impairment Associated with Schizophrenia (CIAS)

10.1176/appi.ajp.2015.15030338 · 2015 · External reference

Alteration of BACE1-dependent NRG1/ErbB4 signaling and schizophrenia-like phenotypes in BACE1-null mice

10.1073/pnas.0710373105 · 2008 · External reference

Neuregulin1 signaling promotes dendritic spine growth through kalirin

10.1111/jnc.12330 · 2013 · External reference

Translating the N-methyl-d-aspartate receptor antagonist model of schizophrenia to treatments for cognitive impairment in schizophrenia

10.1017/s1461145713000928 · 2013 · External reference

Neurocognitive effects of antipsychotic medications in patients with chronic schizophrenia in the CATIE Trial

10.1001/archpsyc.64.6.633 · 2007 · External reference

Treatment outcomes of patients with tardive dyskinesia and chronic schizophrenia

10.4088/jcp.09m05793yel · 2011 · External reference

What have we learned about trial design from NIMH-funded pragmatic trials?

10.1038/npp.2010.115 · 2010 · External reference

Cognitive dysfunction, negative symptoms, and tardive dyskinesia in schizophrenia. Their association in relation to topography of involuntary movements and criterion of their abnormality

10.1001/archpsyc.1987.01800220077011 · 1987 · External reference

Attenuation of phencyclidine-induced object recognition deficits by the combination of atypical antipsychotic drugs and pimavanserin (ACP 103), a 5-hydroxytryptamine(2A) receptor inverse agonist

10.1124/jpet.109.156349 · 2010 · External reference

Procedural learning in schizophrenia: further consideration on the deleterious effect of neuroleptics

2000 · External reference

Functions of frontostriatal systems in cognition: comparative neuropsychopharmacological studies in rats, monkeys and humans

10.1016/j.biopsycho.2006.01.005 · 2006 · External reference

A meta-analysis of cognitive change with haloperidol in clinical trials of atypical antipsychotics: dose effects and comparison to practice effects

10.1016/j.schres.2006.08.021 · 2007 · External reference

Improvement in cognitive functions and psychiatric symptoms in treatment-refractory schizophrenic patients receiving clozapine

10.1016/0006-3223(93)90043-d · 1993 · External reference

Cognitive improvement after treatment with second-generation antipsychotic medications in first-episode schizophrenia: is it a practice effect?

10.1001/archpsyc.64.10.1115 · 2007 · External reference

The effects of atypical antipsychotic drugs on neurocognitive impairment in schizophrenia: a review and meta-analysis

10.1093/oxfordjournals.schbul.a033374 · 1999 · External reference

A meta-analysis of neuropsychological change to clozapine, olanzapine, quetiapine, and risperidone in schizophrenia

10.1017/s146114570500516x · 2005 · External reference

Long-term neurocognitive effects of antipsychotics in schizophrenia: a network meta-analysis

10.1007/s00228-013-1600-y · 2014 · External reference

Antipsychotic effects on cognition in schizophrenia: a meta-analysis of randomised controlled trials

10.4321/s0213-61632009000200002 · 2009 · External reference

Second-generation antipsychotic effect on cognition in patients with schizophrenia—a meta-analysis of randomized clinical trials

10.1111/acps.12374 · 2015 · External reference

Cognitive improvement in schizophrenic patients does not require a serotonergic mechanism: randomized controlled trial of olanzapine vs amisulpride

10.1038/sj.npp.1300626 · 2005 · External reference

The role of 5-hydroxytryptamine 7 receptors in the phencyclidine-induced novel object recognition deficit in rats

10.1124/jpet.111.180638 · 2011 · External reference

Effects of clozapine on cognitive function in schizophrenia

1994 · External reference

Long-term neurocognitive effects of olanzapine or low-dose haloperidol in first-episode psychosis

10.1016/j.biopsych.2005.06.022 · 2006 · External reference

Early-stage Schizophrenia Outcome Study I: neurocognitive effects of first- and second-generation antipsychotic drugs in early-stage schizophrenia: a naturalistic 12-month follow-up study

10.1016/j.neulet.2011.08.027 · 2011 · External reference

Neurocognitive effects of clozapine, olanzapine, risperidone, and haloperidol in patients with chronic schizophrenia or schizoaffective disorder

10.1176/appi.ajp.159.6.1018 · 2002 · External reference

D(1) receptor agonists reverse the subchronic phencyclidine (PCP)-induced novel object recognition (NOR) deficit in female rats

10.1016/j.bbr.2012.09.030 · 2013 · External reference

Molecular and cellular cognitive studies of the role of synaptic plasticity in memory

10.1002/neu.10169 · 2003 · External reference

Neurocognitive-genetic and neuroimaging-genetic research paradigms in schizophrenia and bipolar disorder

10.1007/s00702-011-0672-z · 2011 · External reference

Anatomical specificity in the modulation of activity-regulated genes after acute or chronic lurasidone treatment

10.1016/j.pnpbp.2013.12.008 · 2014 · External reference

The cognitive genetics of neuropsychiatric disorders

10.1007/7854_2011_188 · 2012 · External reference

Increased grey matter densities in schizophrenia patients with negative symptoms after treatment with quetiapine: a voxel-based morphometry study

10.1097/yic.0b013e32831daf6c · 2009 · External reference

A six month randomized controlled trial of long acting injectable risperidone 50 and 100mg in treatment resistant schizophrenia

10.1016/j.schres.2014.02.015 · 2014 · External reference

In vivo actions of atypical antipsychotic drug on serotonergic and dopaminergic systems

10.1016/s0079-6123(08)00909-6 · 2008 · External reference

Selective dopamine D4 receptor agonist (A-412997) improves cognitive performance and stimulates motor activity without influencing reward-related behaviour in rat

10.1097/fbp.0b013e32831c3b06 · 2008 · External reference

Dementia praecox redux: a systematic review of the nicotinic receptor as a target for cognitive symptoms of schizophrenia

10.1177/0269881114564096 · 2015 · External reference

Muscarinic agonists and antagonists in schizophrenia: recent therapeutic advances and future directions

10.1007/978-3-642-23274-9_8 · 2012 · External reference

The procognitive effects of 5-HT6 receptor ligands in animal models of schizophrenia

10.1515/revneuro-2014-0005 · 2014 · External reference

Serotonergic 5-HT7 receptors and cognition

10.1515/revneuro-2013-0066 · 2014 · External reference

Functional and dysfunctional synaptic plasticity in prefrontal cortex: roles in psychiatric disorders

10.1016/j.biopsych.2009.08.026 · 2010 · External reference

Distributed network actions by nicotine increase the threshold for spike-timing-dependent plasticity in prefrontal cortex

10.1016/j.neuron.2007.03.006 · 2007 · External reference

Clozapine ameliorates epigenetic and behavioral abnormalities induced by phencyclidine through activation of dopamine D1 receptor

10.1017/s1461145713001466 · 2014 · External reference

Immature dentate gyrus: an endophenotype of neuropsychiatric disorders

10.1155/2013/318596 · 2013 · External reference

Synaptotagmin IV: biochemistry, genetics, behavior, and possible links to human psychiatric disease

10.1385/mn:23:2-3:173 · 2001 · External reference

The Neuroplastin adhesion molecules: key regulators of neuronal plasticity and synaptic function

10.1111/jnc.12816 · 2014 · External reference

Storage, recall, and novelty detection of sequences by the hippocampus: elaborating on the SOCRATIC model to account for normal and aberrant effects of dopamine

10.1002/hipo.1071 · 2001 · External reference

Neurophysiological and computational principles of cortical rhythms in cognition

10.1152/physrev.00035.2008 · 2010 · External reference

Mouse behavioral endophenotypes for schizophrenia

10.1016/j.brainresbull.2010.04.008 · 2010 · External reference

Behavioral animal models to assess pro-cognitive treatments for schizophrenia

10.1007/978-3-642-25758-2_3 · 2012 · External reference

Does stimulation of 5-HT(1A) receptors improve cognition in schizophrenia?

10.1016/j.bbr.2008.05.016 · 2008 · External reference

Combined serotonin (5-HT) agonism, 5-HT and dopamine D receptor antagonism reproduces atypical antipsychotic drug effects on phencyclidine-impaired novel object recognition in rats

2014 · External reference